Erol Wiegert

578 total citations
13 papers, 273 citations indexed

About

Erol Wiegert is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Erol Wiegert has authored 13 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Genetics and 3 papers in Molecular Biology. Recurrent topics in Erol Wiegert's work include CAR-T cell therapy research (6 papers), Virus-based gene therapy research (4 papers) and Cancer Research and Treatments (3 papers). Erol Wiegert is often cited by papers focused on CAR-T cell therapy research (6 papers), Virus-based gene therapy research (4 papers) and Cancer Research and Treatments (3 papers). Erol Wiegert collaborates with scholars based in Germany, United States and Netherlands. Erol Wiegert's co-authors include Sebastian Härtter, Harm Peters, Jeffrey Friedman, Dmytro Khadzhynov, Stephan Formella, Karl‐Heinz Liesenfeld, Thorsten Lehr, Viktoria Moschetti, Andreas Clemens and Hans‐H. Neumayer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Erol Wiegert

13 papers receiving 267 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erol Wiegert Germany 8 159 110 62 49 30 13 273
Jun Yuan China 10 91 0.6× 12 0.1× 75 1.2× 22 0.4× 28 0.9× 24 287
Taylor I. Liu United States 6 321 2.0× 19 0.2× 55 0.9× 18 0.4× 7 0.2× 10 378
Meera Marji United States 7 47 0.3× 28 0.3× 36 0.6× 8 0.2× 20 0.7× 9 135
Lihui Zheng China 9 150 0.9× 5 0.0× 69 1.1× 14 0.3× 23 0.8× 43 262
Luka Nicin Germany 8 133 0.8× 4 0.0× 109 1.8× 37 0.8× 41 1.4× 12 389
Mayumi Kodama Japan 9 18 0.1× 8 0.1× 62 1.0× 37 0.8× 38 1.3× 14 262
Marianthi Papagianni Greece 9 35 0.2× 14 0.1× 25 0.4× 10 0.2× 11 0.4× 18 244
Yingchun Tian China 6 243 1.5× 37 0.3× 66 1.1× 4 0.1× 4 0.1× 7 336
Jia-Ning Gu China 14 326 2.1× 12 0.1× 87 1.4× 4 0.1× 8 0.3× 26 411
Zsolt Pécsvárady Hungary 7 17 0.1× 22 0.2× 16 0.3× 9 0.2× 25 0.8× 15 170

Countries citing papers authored by Erol Wiegert

Since Specialization
Citations

This map shows the geographic impact of Erol Wiegert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erol Wiegert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erol Wiegert more than expected).

Fields of papers citing papers by Erol Wiegert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erol Wiegert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erol Wiegert. The network helps show where Erol Wiegert may publish in the future.

Co-authorship network of co-authors of Erol Wiegert

This figure shows the co-authorship network connecting the top 25 collaborators of Erol Wiegert. A scholar is included among the top collaborators of Erol Wiegert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erol Wiegert. Erol Wiegert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Mackensen, Andréas, John B.A.G. Haanen, Christian Koenecke, et al.. (2023). CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.. Journal of Clinical Oncology. 41(16_suppl). 2518–2518. 5 indexed citations
2.
Iwamoto, Fábio M., Vinai Gondi, Nicholas Butowski, et al.. (2022). CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. 24(Supplement_7). vii83–vii83. 2 indexed citations
3.
Naik, Shruthi, Bradley C. Leibovich, Tanner Miest, et al.. (2022). Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.. Journal of Clinical Oncology. 40(6_suppl). 509–509. 7 indexed citations
4.
Haanen, John B.A.G., Andréas Mackensen, Christian Koenecke, et al.. (2022). Abstract CT002: BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors. Cancer Research. 82(12_Supplement). CT002–CT002. 16 indexed citations
5.
Haanen, J.B.A.G., Andréas Mackensen, Christian Koenecke, et al.. (2021). LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors. Annals of Oncology. 32. S1392–S1392. 7 indexed citations
6.
7.
Buisseret, Laurence, Sylvie Rottey, Johann S. de Bono, et al.. (2021). Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.. Journal of Clinical Oncology. 39(15_suppl). 2562–2562. 15 indexed citations
8.
Mackensen, Andréas, Christian Koenecke, Winfried Alsdorf, et al.. (2021). 958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors. SHILAP Revista de lepidopterología. A1008–A1008. 15 indexed citations
9.
Merchan, Jaime R., Manish R. Patel, Timothy P. Cripe, et al.. (2020). Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3090–3090. 12 indexed citations
10.
Sznol, Mario, Jose Lutzky, Alex A. Adjei, et al.. (2020). Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma.. Journal of Clinical Oncology. 38(15_suppl). TPS3161–TPS3161. 1 indexed citations
11.
Formella, Stephan, Erol Wiegert, Viktoria Moschetti, et al.. (2013). Effective elimination of dabigatran by haemodialysis. Thrombosis and Haemostasis. 109(4). 596–605. 159 indexed citations
12.
Wagner, Frank, Marie‐Pierre Malice, Erol Wiegert, et al.. (2012). A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans. Journal of Hypertension. 30(4). 819–827. 11 indexed citations
13.
Turpeinen, Anu M., Salme Järvenpää, Erol Wiegert, et al.. (2011). Ile-Pro-Pro and Val-Pro-Pro Tripeptide-Containing Milk Product has Acute Blood Pressure Lowering Effects in Mildly Hypertensive Subjects. Clinical and Experimental Hypertension. 33(6). 388–396. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun Yuan Breakdown of academic impact, for papers by Taylor I. Liu Breakdown of academic impact, for papers by Meera Marji Breakdown of academic impact, for papers by Lihui Zheng Breakdown of academic impact, for papers by Luka Nicin Breakdown of academic impact, for papers by Mayumi Kodama Breakdown of academic impact, for papers by Marianthi Papagianni Breakdown of academic impact, for papers by Yingchun Tian Breakdown of academic impact, for papers by Jia-Ning Gu Breakdown of academic impact, for papers by Zsolt Pécsvárady
Rankless by CCL
2026